Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter

The American Journal of Cardiology
Isabelle C Van GelderK I Lie

Abstract

The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Eighty-one patients were randomized to flecainide treatment or no treatment. Baseline characteristics of both groups were comparable. Compared to previous studies, patients could be classified as difficult-to-treat patients. Multiple regression analysis showed New York Heart Association class I for exercise tolerance (p = 0.0004) and flecainide treatment (p = 0.01) to be the main factors increasing the arrhythmia-free episode. However, Mantel-Cox lifetable analysis did not reveal significant differences between arrhythmia-free survival curves of both treatment groups. In the flecainide-treated group, 9% of patients experienced side effects, mostly related to negative dromotropic effects. The incidence of ventricular proarrhythmia in this group of patients was low. Thus, flecainide may be effective in postponing arrhythmia recurrence, even in difficult-to-treat patients. Caution should be excercised in treating patients with underlying conduction disturbances, sick sinus syndrome or characteristics favoring development of ventricular proarrhythmia.

References

Jan 1, 1989·Journal of Cardiovascular Pharmacology·L M van WijkK I Lie
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Jan 1, 1989·The American Journal of Cardiology·I C Van GelderK I Lie
Jan 15, 1989·The American Journal of Cardiology·H C DittrichP H Nicod
Jun 1, 1987·The American Journal of Cardiology·E BernsG V Naccarelli
Aug 25, 1988·The American Journal of Cardiology·J L AndersonP A Fredell
Dec 1, 1988·The American Journal of Cardiology·H J CrijnsK I Lie
Aug 1, 1987·Archives of Internal Medicine·R D BlevinsM Rubenfire
Oct 1, 1988·Journal of the American College of Cardiology·E M AntmanP L Friedman
Sep 1, 1986·The American Journal of Cardiology·A BorgeatU Sigwart
Jan 1, 1986·The American Journal of Cardiology·R L GoldJ S Alpert
Dec 1, 1985·Journal of the American College of Cardiology·L N HorowitzH R Kay
Nov 1, 1970·British Heart Journal·P SzekelyG A Batson
Feb 27, 1984·The American Journal of Cardiology·N A EstesJ N Ruskin
Nov 1, 1980·British Heart Journal·C E Robertson, H C Miller

❮ Previous
Next ❯

Citations

Apr 1, 1995·International Journal of Cardiology·M L SedgwickS M Cobbe
Nov 15, 1993·Journal of the American College of Cardiology·A T GosselinkK I Lie
Sep 19, 1997·The American Journal of Cardiology·J F LeclercqP Coumel
Jan 7, 1998·The American Journal of Cardiology·G R SimonsE L Pritchett
Feb 3, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Jurren M van OpstalHarry J G M Crijns
Sep 30, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammUNKNOWN ESC Committee for Practice Guidelines
Jan 14, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Nick FreemantleMatthew Reynolds
Sep 1, 1991·British Journal of Clinical Pharmacology·K S Channer
Dec 1, 1992·Pacing and Clinical Electrophysiology : PACE·B OlshanskyR J Hariman
Dec 1, 1993·Pacing and Clinical Electrophysiology : PACE·E Grey, D I Silverman
May 1, 1994·Pacing and Clinical Electrophysiology : PACE·M A Fromer
Nov 14, 1997·Pacing and Clinical Electrophysiology : PACE·I C Van Gelder, H J Crijns
Nov 14, 1997·Pacing and Clinical Electrophysiology : PACE·A CapucciD Aschieri
May 30, 1998·Pacing and Clinical Electrophysiology : PACE·J KassotisJ A Reiffel
Nov 1, 1994·Journal of Cardiovascular Electrophysiology·R H Falk, R I Fogel
Oct 1, 1995·Journal of Cardiovascular Electrophysiology·E M Antman
May 9, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Yasuhiro YoshigaMasunori Matsuzaki
Nov 26, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Yasuo OkumuraKatsuo Kanmatsuse
Mar 8, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Hanney Gonna, Mark M Gallagher
Feb 1, 2014·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Lars B van MiddendorpFrits W Prinzen
Nov 18, 1997·Journal of Cardiovascular Electrophysiology·L I Ganz, E M Antman
Jul 1, 1997·Journal of Cardiovascular Electrophysiology·R D Riley, E L Pritchett
Nov 4, 2016·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Alessandro CapucciFederico Guerra
Apr 21, 2012·Journal of Cardiothoracic and Vascular Anesthesia·Robert H ThieleElliott Bennett-Guerrero
Feb 19, 2011·The Canadian Journal of Cardiology·Anne M GillisUNKNOWN CCS Atrial Fibrillation Guidelines Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.